ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02455622
Recruitment Status : Active, not recruiting
First Posted : May 28, 2015
Last Update Posted : May 22, 2018
Sponsor:
Information provided by (Responsible Party):
Shire

Brief Summary:
This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.

Condition or disease Intervention/treatment Phase
Hunter Syndrome Drug: Elaprase for intravenous (IV) infusion Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
Actual Study Start Date : October 28, 2015
Estimated Primary Completion Date : February 1, 2022
Estimated Study Completion Date : August 1, 2022


Arm Intervention/treatment
Experimental: Enrolled Patients
Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are <6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were < 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
Drug: Elaprase for intravenous (IV) infusion
Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
Other Name: Idursulfase




Primary Outcome Measures :
  1. Change in height [ Time Frame: Screening to End-of-Study (5-10 years) ]
  2. Change in weight Z-scores [ Time Frame: Screening to End-of-Study (5-10 years) ]
  3. Change in neurological examination to evaluate long-term safety in patient [ Time Frame: Screening to End-of-Study (5-10 years) ]
  4. Number of participants with adverse events as measured by type, severity, and relationship to treatment [ Time Frame: Screening to End-of-Study (5-10 years) ]
  5. Change in clinical laboratory testings as measured by urinalysis to evaluate long-term safety in patients [ Time Frame: Screening to End-of-Study (5-10 years) ]
  6. Change in clinical laboratory testings as measured by serum chemistry to evaluate long-term safety in patients [ Time Frame: Screening to End-of-Study (5-10 years) ]
  7. Change in clinical laboratory testings as measured by hematology to evaluate long-term safety in patients [ Time Frame: Screening to End-of-Study (5-10 years) ]

Secondary Outcome Measures :
  1. Urinary glycosaminoglycans (uGAG) levels normalized to urine creatinine [ Time Frame: Screening to End-of-Study (5-10 years) ]
  2. Normalized uGAG divided by upper limit of normal for age (uGAG/ULN) every 12 months [ Time Frame: Baseline to End-of-Study (5-10 years) ]
  3. Joint mobility, as measured by Joint Range of Motion (JROM) scores, including global, upper-limb, and lower-limb joint scores [ Time Frame: Screening to End-of-Study (5-10 years) ]
  4. Distance walked, as measured by the Six Minute Walk Test (6MWT) [ Time Frame: Screening to End-of-Study (5-10 years) ]
  5. Quality of Life, as measured by the Hunter-Syndrome Functional Outcome in Clinical Understanding Scale [ Time Frame: Screening to End-of-Study (5-10 years) ]
  6. Impact of illness on ability to function in daily life, as measured by the Childhood Health Assessment Questionnaire (CHAQ Parent Report) [ Time Frame: Screening to End-of-Study (5-10 years) ]
  7. Adaptive behavior, as measured by the Vineland Adaptive Behavior Scales (VABS II) [ Time Frame: Screening to End-of-Study (5-10 years) ]
  8. Change in anti-idursulfase antibodies in serum [ Time Frame: Screening to End-of-Study (5-10 years) ]
    number and percentage of patients testing anti-idursulfase antibody positive and negative at each time point



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 6 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Group 1: Prospective Patient Group

    1. The patient is male.
    2. The patient is Elaprase-naïve at study entry.
    3. The patient must have a documented diagnosis of MPS II. Of the 3 criteria below, the combinations (3a AND 3b) or (3a AND 3c) will be accepted as diagnostic of MPS II:

      1. The patient has a deficiency in I2S enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory's normal range). AND
      2. The patient has a documented mutation in the I2S gene. OR
      3. The patient has a normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the normal range of measuring laboratory).
    4. The patient will be <6 years of age at the start of Elaprase treatment.
    5. The patient, patient's parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient's parent(s) or legally authorized guardian(s) and the patient's assent, as relevant, must be obtained.

Group 2: Retrospective Data Inclusion Criteria:

Retrospective Patient Group patients will be enrolled in HOS and not Study SHP-ELA-401; however, their growth data may be included in the analysis for Study SHP-ELA-401 if the following data inclusion criteria are met.

  1. The patient is male.
  2. The patient is enrolled in HOS.
  3. The patient was <6 years of age at the start of Elaprase treatment.
  4. The patient received Elaprase weekly treatment for at least 5 years.
  5. The patient had a height assessment and a weight assessment documented within 3 months before or after Elaprase treatment start.
  6. The patient has had annual height and weight assessments from start of Elaprase through age 10 years.
  7. The patient, patient's parent(s), or legally authorized guardian(s) agree(s) to data collection.
  8. The patient, patient's parent(s), or legally authorized guardian(s) must have signed an IRB/IEC-approved informed consent form after all relevant aspects of the HOS study have been explained and discussed. Consent of the patient's parent(s) or legally authorized guardian(s) and the patient's assent, as relevant, must be obtained.

Exclusion Criteria:

  • Group 1: Prospective Patient Group

    1. The patient has received treatment with any investigational drug or device within the 30 days prior to study entry.
    2. The patient has received or is receiving treatment with idursulfase-IT.
    3. The patient has received growth hormones, a cord blood infusion, or a bone marrow transplant at any time.
    4. The patient has received blood product transfusions within 90 days prior to Screening.
    5. The patient is unable to comply with the protocol as determined by the Investigator.

Group 2: Retrospective Data Exclusion Criteria:

HOS patients that meet the following criteria are not eligible to be included into the Study SHP-ELA-401 Primary Growth Analysis:

1. Patient was treated with growth hormone or other medications or interventions intended to promote growth in the time period covered by the analysis.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02455622


Locations
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
Dominican Republic
Hospital Infantil Dr Robert Reid Cabral
Santo Domingo, Dominican Republic, 10101
Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany, 55131
Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia, 50586
Philippines
Philippine General Hospital
Manila, Philippines, 1000
Serbia
Mother and Child Health Care Institute of Serbia Dr Vukan Cupic
Beograd, Serbia, 11000
Thailand
Chulalongkorn University
Bangkok, Thailand, 10330
Vietnam
National Pediatrics Hospital
Hanoi, Vietnam
Sponsors and Collaborators
Shire
Investigators
Study Director: Shire Study Physician Shire Shire

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT02455622     History of Changes
Other Study ID Numbers: SHP-ELA-401
First Posted: May 28, 2015    Key Record Dates
Last Update Posted: May 22, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Mucopolysaccharidosis II
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Mucopolysaccharidoses
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Lysosomal Storage Diseases
Mucinoses
Connective Tissue Diseases
Metabolic Diseases